Last reviewed · How we verify
An Open Label, Registry Study of the Safety of Iluvien® 190 Micrograms Intravitreal Implant in Applicator (IRISS)
The study will include any patient treated with Iluvien at designated sites in European countries where marketing authorization has been granted in order to obtain broader safety and usage information.
Details
| Lead sponsor | Alimera Sciences |
|---|---|
| Status | UNKNOWN |
| Enrolment | 559 |
| Start date | 2013-12 |
| Completion | 2020-01 |
Conditions
- Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies
Primary outcomes
- Number of participants with adverse events. — 5 years
Countries
United States